Cargando…

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer

OBJECTIVE: To carry out the meta-analysis on the relationship between the expression of nucleotide excision repair cross-complementary enzyme 1 (ERCC1) protein and platinum chemosensitivity in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: The literature on the expression of ERC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guoping, Cheng, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210550/ https://www.ncbi.nlm.nih.gov/pubmed/32419821 http://dx.doi.org/10.1155/2020/7376568

Ejemplares similares

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: LIU, YONG-PING, et al.
Publicado: (2013)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study
por: Abdalkhalek, Esraa S., et al.
Publicado: (2022)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
por: Han, Yali, et al.
Publicado: (2016)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy
por: Zhang, Ruoxin, et al.
Publicado: (2017)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy
por: Qiao, Hongwei, et al.
Publicado: (2014)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N(2) non-small cell lung cancer
por: Yan, Dong, et al.
Publicado: (2013)

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis
por: Yang, Yanlong, et al.
Publicado: (2014)

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
por: Xu, Meizhen, et al.
Publicado: (2017)

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
por: Glaysher, Sharon, et al.
Publicado: (2009)

Polymorphisms in ERCC2 and ERCC5 and Risk of Prostate Cancer: A Meta-Analysis and Systematic Review
por: Liu, Yi, et al.
Publicado: (2018)

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel
por: Wang, Lifeng, et al.
Publicado: (2008)

Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer
por: Lin, Sheng, et al.
Publicado: (2021)

Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer
por: JIANG, HONG, et al.
Publicado: (2013)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Polymorphisms in ERCC4 and ERCC5 and risk of cancers: Systematic research synopsis, meta-analysis, and epidemiological evidence
por: Zuo, Chunjian, et al.
Publicado: (2022)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer
por: Jian-wei, Bi, et al.
Publicado: (2013)

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma
por: Zhang, Wen, et al.
Publicado: (2012)

Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression
por: Honma, Helen Naemi, et al.
Publicado: (2018)

DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance
por: Wang, Shuai, et al.
Publicado: (2016)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance
por: Wang, Weiwei, et al.
Publicado: (2017)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
por: Hung, Man-Hsin, et al.
Publicado: (2015)

Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma
por: Feng, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p3s3549b2d07fii34vp4qrbhnh